[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343094-105":59,"doc-detail-343094-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","identification-of-potential-therapeutic-targets-for-skin-cutaneous-melanoma-on-the-basic-of-transcriptomics","Identification of potential therapeutic targets for skin cutaneous melanoma on the basic of transcriptomics","","Advanced skin cutaneous melanoma (SKCM) accounts for most skin-cancer related deaths, yet beyond the rare BRAF V600F mutation there are few other effective therapeutic targets. Mendelian randomization used cis-eQTL and SMR to test SKCM outcomes, applying colocalization assays and HEIDI tests to assess shared SNP-driven effects. Replication and protein–protein interaction network analyses supported the identified genes. DGIdb-based druggability predictions and molecular docking supported medicinal value, while transcriptome differential analysis distinguished normal versus SKCM expression profiles.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/identification-of-potential-therapeutic-targets-for-skin-cutaneous-melanoma-on-the-basic-of-transcriptomics/343094/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/identification-of-potential-therapeutic-targets-for-skin-cutaneous-melanoma-on-the-basic-of-transcriptomics/343094.png","ImageObject",300,407,{"name":92,"@type":93},"Ezra","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study’s goal for skin cutaneous melanoma?","Question",{"text":112,"@type":113},"To identify potential therapeutic targets for SKCM using transcriptomics-based genetic evidence.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were causal associations assessed in this work?",{"text":117,"@type":113},"The study used SMR with cis-eQTL exposure and SKCM as the outcome, supported by colocalization assays and HEIDI tests, followed by replication.",{"name":119,"@type":110,"acceptedAnswer":120},"Which genes and evidence classes were highlighted?",{"text":121,"@type":113},"Thirteen genes were associated with SKCM risk, including Class 1 evidence targets (SOX4, MAFF) and Class 2 evidence targets for the remaining genes (except HELZ2).","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},343094,1790193587,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","DOI: 10.1111/srt.13916  \nORIGINAL ARTICLE  \nIdentification of potential therapeutic targets for skin cutaneous melanoma on the basic of transcriptomics  \nFengling Shi1, 2  Tao Li1, 2  Huiling Shi1, 2  Yushan Wei1, 2  Juan Wang1, 2  Canyu Liu3  Ruirong Liang1, 2,4  \n1 Department of Oncology, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Medical Center of Soochow University, Suzhou, China  \n2 Division of Clinical Oncology, Medical Center of Soochow University, Suzhou, China  \n3 Department of Radiation Oncology, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Medical Center of Soochow University, Suzhou, China  \n4 Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China  \nCorrespondence  \nCanyu Liu, Department of Radiation Oncology, The Fourth Affiliated Hospital of Soochow University, 9th Chongwen Road, Suzhou, 215124, China.  \n[Email:](Email: canyuliu@126.com)[ canyuliu@126.com](Email: canyuliu@126.com)  \nRongrui Liang, Department of Oncology, The Fourth Affiliated Hospital of Soochow University, 9th Chongwen Road, Suzhou, 215124, China.  \nEmail: [lengbeng@suda.edu.cn](lengbeng@suda.edu.cn)  \nFunding information  \nNational Natural Science Foundation of China, Grant/Award Number: 81402477; Natural Science Foundation of Jiangsu Province of China, Grant/Award Number: BK20140295; Clinical Research Project of Wu Jieping Medical Foundation, Grant/Award Number:  \n320.6750.2021-16-62; Suzhou Science and Technology Plan, Grant/Award Numbers:  \nSZM2021012, SKY2022092, SZM2023031; Beijing Xisike Clinical Oncology Research Foundation, Grant/Award Number:  \nY-HH202101-0059; Clinical Medicine peak project of Soochow Medical College, Soochow University, Grant/Award Number: ML42900423  \nAbstract  \nBackground:Advanced skin cutaneous melanoma(SKCM)is responsiblefor the majority of skin cancer-related deaths. Apart from the rare BRAF V600F mutation, which can be targeted with specific drugs, there are currently no other novel effective therapeutic targets.  \nMethods: We used SMR analysis with cis-expressed quantitative trait locus (cis-eQTL) as the exposure variable and SKCM as the outcome variable to identify potential therapeutic targets for SKCM. Colocalization assays and HEIDI tests are used to test whether SKCM risk and gene expression are driven by common SNPs. Replication analysis further validated the findings, and we also constructed protein–protein interaction networks to explore the relationship between the identified genes and known SKCM targets. Drug prediction and molecular docking further validated the medicinal value of drug targets. Transcriptome differential analysis further validated that there were differences between normal tissues and SKCMfor the selected targets.  \nResults: We identified 13 genes significantly associated with the risk of SKCM, including five protective genes and eight harmful genes. The HEIDI test and co-localization analysis further indicates a causal association between genes (SOX4, MAFF) and SKCM, categorized as Class 1 evidence targets. The remaining 11 genes, except for HELZ2 show a moderately causal association with SKCM, categorized as Class 2 evidence targets. Target druggability predictions from DGIdb suggest that SOX4, MAFF, ACSF3, CDK10, SPG7, and TCF25 are likely to be future drug targets.  \nConclusion: The study provides genetic evidence for targeting available drug genes for the treatment of SKCM.  \nFengling shi and Tao Li contributed equally to this study.  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.  \n© 2024 The Author(s). Skin Research and Technology published by John Wiley & Sons Ltd.  \nSkin Res Technol. 2024;30:e13916.  \n[https://doi.org/10.1111/srt.1","cbCaimqPWmYeydEQ","https://ap.wps.com/l/cbCaimqPWmYeydEQ","pdf",3532974,"English","# Abstract\n# Introduction\n# Methods\n# Results\n# Conclusion","[{\"question\":\"What was the study’s goal for skin cutaneous melanoma?\",\"answer\":\"To identify potential therapeutic targets for SKCM using transcriptomics-based genetic evidence.\"},{\"question\":\"How were causal associations assessed in this work?\",\"answer\":\"The study used SMR with cis-eQTL exposure and SKCM as the outcome, supported by colocalization assays and HEIDI tests, followed by replication.\"},{\"question\":\"Which genes and evidence classes were highlighted?\",\"answer\":\"Thirteen genes were associated with SKCM risk, including Class 1 evidence targets (SOX4, MAFF) and Class 2 evidence targets for the remaining genes (except HELZ2).\"}]","Identification of potential therapeutic targets for skin cutaneous melanoma on the basic of transcriptomics | PDF",1790049835,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d7fe40c03728d1fb1f14f4134f82dd8e.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/34c8e6e36ab4089e12b05811b0478d37.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/77ec49bcec57da71cbde0af294e811b1.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/acfc679d8a9bfc8f574cf095d8c798d6.webp",980,1287]